Navigation Links
Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
Date:8/23/2007

CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the company submitted a draft clinical study protocol to the FDA for compassionate use of the investigational product Hemopure (HBOC-201) in the United States. The proposed open label study would make Hemopure available to patients for the treatment of life threatening or potentially life threatening anemia on a compassionate use basis where blood transfusion is not an option.

The product has been available for compassionate use since December 2006. Under the existing program the company evaluates individual requests from treating physicians for specific patients. If the patient is deemed an appropriate candidate for treatment, the FDA is contacted and a single patient IND is requested. To date the FDA has authorized shipment of Hemopure for 20 patients. Of the treated patients, four were experiencing severe anemia secondary to the management and treatment of leukemia and lymphoma. The balance of the compassionate use cases were for the treatment of blood loss resulting from surgical complications or trauma. The remaining patients who were not treated stabilized at the site by the time the drug was received.

The draft protocol outlines general eligibility criteria that include the following:

-- Severe, life threatening, or potentially life threatening anemia

-- Blood transfusion is not feasible

-- All alternative treatment options have been exhausted

-- Adult male or female - 18 years of age, or child with anemia secondary

to severe burns

The safety, efficacy and pharmacology of Hemopure have been studied in 22 completed clinical trials. An additional four trial
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster ... Saturday, May 18, in Santa Monica, Calif. ... new lung-sparing therapies for MPM, a rare form of ... affects the pleura, the lining of the chest. ... and Blood Institute, the 3rd Annual International Symposium on ...
(Date:5/24/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that Dr. Robert Grieve , the ... Napolitano , executive vice president and chief financial officer, ... is being held May 30, 2013 in New ... The Company,s presentation is scheduled to begin at ...
(Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4
(Date:5/24/2013)... Chronic Fatigue Syndrome has been a mysterious ... fatigue lasting 6 months or longer. Symptoms of Chronic ... impairment, muscle and joint pain without swelling or redness, ... malaise that lasts for more than 24 hours. ... linked to insulin resistance. At a healthy body weight, ...
(Date:5/24/2013)... Today marks the launch of Destination Halifax’s latest ... The redesigned and enhanced Itinerary Builder will help visitors ... computer or mobile device that they can send, save, ... to fill in their date of arrival and length ... of vacation packages, accommodations, restaurants, and things to do ...
(Date:5/24/2013)... May 24, 2013 Bridal Buy ... to announce new 2013 bridesmaid dresses are ... bridesmaid dresses are handcrafted, featured as fine fabrics, elegant ... dress takes great skill and an eye for detailed ... hand-made embroidery, brought to life from patterns and the ...
(Date:5/24/2013)... The leading retail brand Short Dresses ... short prom dresses . Now that is quite unbelievable, especially ... the brand name since its origin. The retailer has already ... now this huge discount offer will be an added bonanza ... highly privileged to announce that Short Dresses is to offer ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 ... the Cellulite Whisperer line, with a ... for Summer Sale" includes two proprietary products, the ... Whisperer® Lotion . , Purchasers receive a report ... , "The Gel has a wonderful grapefruit scent," ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2
... study conducted by researchers say it is a misconception ... older or housebound people.// ,Researchers examined 150 ... levels of vitamin D. Among the participants, all African-American, ... D deficiencies, as were all patients younger than 30. ...
... A pitch-black room may be the healthiest environment for your ... at night // may put children at risk for ... to disrupt the circadian rhythm and suppress the production of ... been shown to protect DNA from oxidative damage. Once damaged, ...
... study shows sinusitis in asthma patients tends to be ... suggest patients // can have dramatic improvement in symptoms ... is used. ,In the study patients with asthma ... polyps, olfactory dysfunction, and nasal congestion compared to patients ...
... new study shows moderate consumption of alcohol may cut ... arteries.// Researchers evaluated 225 men after they had undergone ... open blocked arteries with a stent. Less traumatic than ... cause inflammation resulting in renarrowing of the artery, usually ...
... study researchers say the antidepressant duloxetine, also known ... fibromyalgia in women . Duloxetine works by stopping ... of the brain’s neurotransmitters that are linked to ... that is characterized by body pain, muscle tenderness, ...
... cluster of risk factors known as metabolic syndrome is ... risk factors. // ,Metabolic syndrome has been ... coronary heart disease. Metabolic syndrome includes looking at factors ... has two different definitions including one by the National ...
Cached Medicine News:
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial...
Used after ablation to wash away particulate from anterior & posterior sides of flap & stromal bed. Conforms to the corneal flap. .0mm extension with a 11.0mm radius, Angled tip....
30, 6.0mm from end...
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
Medicine Products: